Patient information sheet
Select the indication for which TPS is being proposed to you. Each sheet states what the published studies show and what they do not show for that specific indication.
Information sheet given before the first session
This document is given to you before your first session, so that you have the time you need to read it, discuss it with your doctor and ask questions. It describes what TPS is, what is expected in your indication, what the published studies establish and what they do not, the adverse effects reported, the contraindications and the cost.
The informed consent form you will be asked to sign refers to this document. Do not sign it if anything remains unclear: ask us to explain — that is what this sheet is for.
1. What is TPS?
"Transcranial" means "through the skull". Transcranial Pulse Stimulation consists of the controlled transmission of acoustic pulses through the scalp and skull, towards the brain regions involved in your condition. The session is carried out seated, without anaesthesia, without injection and without medication. You feel light tapping on the skull.
The acoustic pulses used have been employed in medicine since 1990 under the name "extracorporeal shock waves", notably for tendons, ligaments, muscles and bone. The device used here is the NEUROLITH® by Storz Medical (class IIb medical device, CE marking issued by TÜV Rheinland no. 0197).
2. Why TPS is being proposed to you
In your indication, the objectives of the programme are as follows:
3. What the published studies show
Each item below carries its PubMed identifier (PMID), which allows the original article to be retrieved. Unfavourable or non-significant results are stated on the same footing as favourable ones.
4. What the studies do not show
No result can be guaranteed. The published data describe group averages: they do not predict your individual outcome. Some patients derive no benefit from the programme at all.
5. How the programme runs
The usual programme comprises 6 sessions over 2 to 3 weeks (2 to 3 sessions per week). Certain situations — depression, advanced Alzheimer's or Parkinson's disease — may require 6 to 12 sessions according to the literature. The number retained for you is set out in a personalised quotation given at the first consultation.
- Before the first session — baseline assessment using validated instruments, and verification of contraindications.
- Each session — about 45 minutes of stimulation; allow 90 minutes for the first consultation.
- After the last session — exit assessment using the same instruments, in order to measure objectively what has changed.
- Report — sent to your referring physician at the end of the programme.
- Maintenance sessions — if you are a responder, maintenance sessions may be proposed, usually one approximately every 6 weeks. The benefit of these maintenance sessions is not demonstrated by a controlled trial.
A brain MRI is required: please bring it to the first consultation (CD, USB stick or DICOM files). It is used for the anatomical targeting of the stimulation.
6. How your results are measured
The instruments used in your indication, before and after the programme:
Your results are recorded in a structured follow-up registry, which makes it possible to compare your condition before and after the programme objectively, rather than relying on a general impression.
7. Adverse effects
No serious adverse event has been reported in the published studies, and no brain lesion has been observed on MRI. Mild effects, however, are frequent: it would be inaccurate to present TPS as free of effects. They usually resolve within 24 hours.
The effects reported are: tingling or pain at the application site, fatigue, dizziness, headaches, and more rarely nausea. The published frequencies vary mainly according to how the effects were collected (systematic questionnaire or spontaneous reporting):
| Effect | Published frequency | Source |
|---|---|---|
| Tingling | 57.5% of patients under active stimulation, versus 17.5% under placebo | Qin 2026 n = 80 |
| Pain at the application site | 47.5% versus 10% under placebo; elsewhere 31% of patients, i.e. 4.9% of sessions | Qin 2026 Mitterwallner 2026 n = 88 |
| Fatigue | 33% of patients, i.e. 6.4% of sessions | Mitterwallner 2026 n = 88 |
| Dizziness | 23% of patients, i.e. 4.0% of sessions | Mitterwallner 2026 n = 88 |
| Nausea | rare — 3 patients out of 101 | Radjenovic 2022 n = 101, 990 sessions |
| Transient worsening of mood | 12% of patients in the Alzheimer trial; 6.8% in a series of 88 patients | Matt 2025 Mitterwallner 2026 |
More rarely described: confusion, disorientation, unsteady gait, worsening of a tremor (series of 101 patients, Radjenovic 2022). In the randomised depression trial, at least one adverse effect occurred in 37 patients out of 40 under active stimulation, versus 22 out of 40 under placebo.
8. Contraindications
TPS cannot be offered to you in the following situations:
- Active malignant brain tumour
- Brain surgery within the last 6 months
- Haemorrhagic stroke within the last 6 months
- Metallic intracranial implant
- Implanted pacemaker or defibrillator
- Uncontrolled epilepsy
- Pregnancy
- Corticosteroid therapy within the last 6 weeks
- Active thrombosis
- Haemophilia, coagulation disorder, or anticoagulant at therapeutic dose
These points are asked of you in the preliminary questionnaire. Report them even if you are unsure: it is for the practitioner to assess, not for you to decide.
9. Cost
Fees are unregulated and not reimbursed by the French health insurance system. Payment in instalments is possible on request. A named quotation is given to you before any commitment. If you are covered by a foreign health insurer (Germany, Switzerland), a medical annex setting out the objectives, the measurement instruments and the published references can be attached to your quotation or invoice.
10. Your rights
- No guarantee of result is given to you, by anyone.
- You may refuse or stop the programme at any time, without justification and without consequence for your care elsewhere.
- Your health data are processed in accordance with the GDPR, solely within the context of your care. They are not passed to any third party without your agreement, apart from the referring physician you have designated. (privacy policy)
- The use of your data for research purposes is the subject of a separate, optional agreement, which you may decline without this changing anything about your care.
- You may request a copy of your file and of your signed consent at any time.
Questions
Charles du Teil, physiotherapist–osteopath D.O. — 7 rue Anatole de la Forge,
75017 Paris, France · +33 6 64 99 83 10 · contact@centre-tps-paris.fr
SIRET no. 93250482700012 · RPPS no. 10101761055
All the publications cited are available at centre-tps-paris.fr/litterature.html, sorted by condition, with the PubMed link for every study.
—
Given before the first session. It is referenced by the informed consent form signed at Centre TPS Paris XVII.